Leah Kuntz is the Assistant Managing Editor at Psychiatric Times. She specializes in medicine and healthcare, with a focus on mental health care, psychiatry, and the emerging fields of psychedelic research and therapy. Leah's work has been featured in Drug Topics, NewsBreak, and Psychiatric Times.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Leah's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly in mental health research. Her articles often cite data and include expert commentary, indicating a preference for evidence-based information from authoritative sources.
Given Leah's focus on mental health topics and reliance on data-driven insights, she would likely be receptive to pitches that offer access to new research findings or interviews with experts who can provide valuable commentary based on empirical evidence. Additionally, she may be interested in exclusive insights regarding innovative treatments or therapeutic approaches related to mental health disorders.
While Leah does not have a specified geographic focus, her coverage appears global in scope as it encompasses advancements and research across various areas of mental health without being limited to specific regions.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Leah Kuntz
BioVie completes treatment visits in a phase 2 long COVID trial of bezisterim targeting brain fog and fatigue, with topline results expected September 2026.
By: Leah Kuntz
Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.
New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.
By: Leah Kuntz
A target trial emulation of more than 1.5 million matched adults ties GLP-1 RA initiation to lower mortality and cardiovascular events in serious mental illness.
Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times' September 2026 series.
By: Leah Kuntz
FDA boosts DT120 lysergide ODT after phase 3 shows lasting depression relief; psychedelic tablet also advances for anxiety and other brain disorders.
By: Leah Kuntz
Psychedelic psilocybin therapy shows year-long relief in treatment-resistant depression, with strong response rates and stable safety.
Phase 3 NEJM data show oveporexton improves wakefulness, reduces cataplexy, and boosts quality of life in narcolepsy type 1, with manageable adverse effects.
By: Leah Kuntz
New NIH-funded study probes why many callers avoid returning to 988, linking user experiences and state systems to improve crisis support nationwide.
By: Leah Kuntz
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
